Requisite Capital Management’s Coherus Oncology CHRS Stock Holding History

Requisite Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-35,000	Closed	-$642K	–	64
2020 Q3	$642K	Hold	35,000	–	–	0.22%	28
2020 Q2	$625K	Hold	35,000	–	–	0.24%	36
2020 Q1	$568K	Hold	35,000	–	–	0.25%	23
2019 Q4	$630K	Buy	+35,000	New	+$645K	0.22%	40

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Requisite Capital Management's CHRS Position: Q4 2020 in Review

Requisite Capital Management sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 35,000 shares — an estimated $642K sold.

Requisite Capital Management first reported a position in CHRS in Q4 2019 and held it in 4 quarters. The position peaked at $642K in Q3 2020. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

Requisite Capital Management reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
Requisite Capital Management sold 35,000 Coherus Oncology shares in Q4 2020, an estimated $642K.
Requisite Capital Management first reported a position in Coherus Oncology in Q4 2019 and held it in 4 quarters.
Requisite Capital Management's Coherus Oncology position peaked at $642K in Q3 2020.
196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Requisite Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.